• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy.

作者信息

Lesser R P, Fahn S, Snider S R, Cote L J, Isgreen W P, Barrett R E

出版信息

Neurology. 1979 Sep;29(9 Pt 1):1253-60. doi: 10.1212/wnl.29.9_part_1.1253.

DOI:10.1212/wnl.29.9_part_1.1253
PMID:573405
Abstract

We evaluated the current status of 131 patients with idiopathic parkinsonism who were receiving levodopa therapy. The residual parkinsonian symptoms and signs were tabulated, as were the adverse effects from medication. Response to therapy was correlated with duration of the disease and with duration of treatment. Patients with on-off or wearing-off effects were likely to have been treated for 4 years or longer. Patients treated with levodopa for 4 to 8 years were significantly more impaired with parkinsonism than patients treated for 0 to 3 years, even when patients were matched for total duration of disease. These data suggest that the deterioration of responsiveness after several years of levodopa therapy may be due to the therapy itself. Our findings support the concept that utilization of levodopa therapy should be delayed until a patient becomes significantly impaired in occupational or social situations.

摘要

相似文献

1
Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy.
Neurology. 1979 Sep;29(9 Pt 1):1253-60. doi: 10.1212/wnl.29.9_part_1.1253.
2
From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity.从关期肌张力障碍到峰值剂量舞蹈症。不同丘脑底核活动的临床谱。
Brain. 1999 Jun;122 ( Pt 6):1133-46. doi: 10.1093/brain/122.6.1133.
3
Evidence to support early levodopa therapy in Parkinson disease.
Neurology. 1981 Feb;31(2):125-31. doi: 10.1212/wnl.31.2.125.
4
Parkinson's disease: long-term results of levodopa therapy.帕金森病:左旋多巴治疗的长期结果
Scott Med J. 1982 Oct;27(4):284-7. doi: 10.1177/003693308202700404.
5
[Motor complications in patients with Parkinson disease treated with levodopa].[左旋多巴治疗帕金森病患者的运动并发症]
Neurologia. 1989 Jan-Feb;4(1):4-11.
6
Hemiballism and chorea in a patient with parkinsonism due to a multisystem degeneration.一名因多系统变性导致帕金森综合征的患者出现偏身投掷症和舞蹈症。
Mov Disord. 1992;7(1):71-7. doi: 10.1002/mds.870070115.
7
Six years of high-level levodopa therapy in severely akinetic parkinsonian patients.
Arch Neurol. 1976 May;33(5):333-8. doi: 10.1001/archneur.1976.00500050019004.
8
[Problems of long-term levodopa therapy in Parkinson's disease].[帕金森病长期左旋多巴治疗的问题]
Nihon Rinsho. 1997 Jan;55(1):65-71.
9
Parkinsonism and levodopa: a five-year experience.帕金森综合征与左旋多巴:五年经验
J Clin Pharmacol. 1976 Nov-Dec;16(11-12):652-9. doi: 10.1002/j.1552-4604.1976.tb01505.x.
10
The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.长效多巴胺受体激动剂卡麦角林用于早期帕金森病:一项为期5年的双盲、左旋多巴对照研究的最终结果
CNS Drugs. 2004;18(11):733-46. doi: 10.2165/00023210-200418110-00003.

引用本文的文献

1
Multifunctional role of natural products for the treatment of Parkinson's disease: At a glance.天然产物在帕金森病治疗中的多功能作用:概述
Front Pharmacol. 2022 Oct 6;13:976385. doi: 10.3389/fphar.2022.976385. eCollection 2022.
2
Current Therapies in Clinical Trials of Parkinson's Disease: A 2021 Update.帕金森病临床试验的当前疗法:2021年更新
Pharmaceuticals (Basel). 2021 Jul 25;14(8):717. doi: 10.3390/ph14080717.
3
Characterization of Small-Molecule-Induced Changes in Parkinson's-Related Trafficking via the Nedd4 Ubiquitin Signaling Cascade.
通过 Nedd4 泛素信号级联反应鉴定帕金森相关运输中小分子诱导的变化。
Cell Chem Biol. 2021 Jan 21;28(1):14-25.e9. doi: 10.1016/j.chembiol.2020.10.008. Epub 2020 Nov 10.
4
Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.使用培高利特恢复中间部垂体多巴胺浓度和酪氨酸羟化酶表达水平:来自患有垂体中间部功能减退症的马的证据。
BMC Vet Res. 2020 Sep 25;16(1):356. doi: 10.1186/s12917-020-02565-3.
5
Synthesis and Biological Evaluation of Novel Selenyl and Sulfur-l-Dopa Derivatives as Potential Anti-Parkinson's Disease Agents.新型硒代和硫代 L-多巴衍生物的合成与生物评价作为潜在的抗帕金森病药物。
Biomolecules. 2019 Jun 18;9(6):239. doi: 10.3390/biom9060239.
6
Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.西他列汀和利拉鲁肽调节左旋多巴的作用并减轻鱼藤酮致损伤大鼠的运动障碍。
Neurotox Res. 2019 Apr;35(3):635-653. doi: 10.1007/s12640-019-9998-3. Epub 2019 Jan 23.
7
Functional Connectivity Changes of Key Regions for Motor Initiation in Parkinson's Disease.帕金森病运动起始关键区域的功能连接变化。
Cereb Cortex. 2019 Jan 1;29(1):383-396. doi: 10.1093/cercor/bhy259.
8
Dyskinesias and levodopa therapy: why wait?运动障碍与左旋多巴治疗:为何要等待?
J Neural Transm (Vienna). 2018 Aug;125(8):1119-1130. doi: 10.1007/s00702-018-1856-6. Epub 2018 Feb 10.
9
Sensorimotor adaptation of voice fundamental frequency in Parkinson's disease.帕金森病中语音基频的感觉运动适应性
PLoS One. 2018 Jan 26;13(1):e0191839. doi: 10.1371/journal.pone.0191839. eCollection 2018.
10
The relationships between mild cognitive impairment and phenotype in Parkinson's disease.帕金森病中轻度认知障碍与表型之间的关系。
NPJ Parkinsons Dis. 2015 Aug 27;1:15015. doi: 10.1038/npjparkd.2015.15. eCollection 2015.